Insider

Vertex Pharmaceuticals reports third-quarter 2026 results

Vertex Pharmaceuticals reported its financial results for the third quarter of 2026, recording non-GAAP net income of $1.2 billion.

Verified against 2 archived primary sources · SHA-256 recorded Inspect sources & citations ↓
a long hallway with pictures on the walls
Photo by zhang shuaizhang on Unsplash
$1.2 billion
Non-GAAP net income
$9.8 billion
Cash and marketable securities

Key points

  • Cash and marketable securities totaled $9.8 billion at the end of September, down from $12.3 billion at year-end 2025.
  • Rising operating expenses from product development and asset integration may limit earnings growth.

Financial and operating performance

Cash and marketable securities totaled $9.8 billion at the end of September, down from $12.3 billion at year-end 2025. The decrease followed the $9.0 billion net acquisition of Crinetics Pharmaceuticals and share repurchases, partially offset by a $4.5 billion term loan.

CASGEVY revenue was $99 million, while JOURNAVX generated $58 million in the third quarter. In September, the company recorded its first $10 million in revenue from PALSONIFY, a drug acquired with Crinetics.

Cash and cash equivalents

September 30, 2026$9.8 billionDecember 31, 2025$12.3 billion
Data from the original sources listed alongside.

Revenue by quarter, $B

2.9Q4 '24*35.2%2.8Q1 '2522.7%3Q2 '2538.8%3.1Q3 '2538.6%3.2Q4 '25*37.8%3Q1 '2638.1%3.3Q2 '2637.4%3.4Q3 '2620.7%
Bottom row: operating margin (operating income divided by revenue). Q4 = fiscal year minus the three quarters reported on their own. Revenue as the company tagged it in its SEC filings (XBRL). Guidance is the company's own, not our forecast.

Sector context: 36 covered companies in Health Care reported a median revenue change of +7.2% YoY in their latest filings.

Shareholder risks

Rising operating expenses from product development and asset integration may limit earnings growth. Additionally, the company’s new debt structure for acquisitions impacts its liquidity.

Key events to monitor

Shareholders should watch for a U.S. regulatory decision on povetacicept, expected by November 30, 2026. The company also plans to release interim results for VX-670, a treatment for myotonic dystrophy.

Original sources

  1. 8-K EX-99.1 filing, November 2, 2026November 2, 2026SHA-256 of our archived copy d244ff1d2a29…
  2. 8-K filing, November 2, 2026November 2, 2026SHA-256 of our archived copy 599b60a0fc08…
Cite this article

The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.

Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards